Key Points
- Cosmos Health CEO Grigorios Siokas bought 90,325 shares on Jan. 23 at $0.50, raising his stake to 8,182,120 shares valued at about $4.09 million (a 1.12% ownership increase).
- Aggressive insider buying: Siokas purchased roughly 1.85 million shares across multiple trades since late November into January at about $0.50 per share, indicating sustained insider accumulation.
- Fundamentals and sentiment remain weak: Cosmos Health has a market cap near $18.95 million, reported negative EPS and margins (missing estimates), and the stock carries a consensus "Sell" rating (Weiss D-).
Cosmos Health Inc. (NASDAQ:COSM - Get Free Report) CEO Grigorios Siokas bought 90,325 shares of the company's stock in a transaction on Friday, January 23rd. The stock was bought at an average price of $0.50 per share, with a total value of $45,162.50. Following the completion of the acquisition, the chief executive officer owned 8,182,120 shares in the company, valued at $4,091,060. This represents a 1.12% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Grigorios Siokas also recently made the following trade(s):
- On Tuesday, January 20th, Grigorios Siokas purchased 353,321 shares of Cosmos Health stock. The shares were purchased at an average cost of $0.50 per share, for a total transaction of $176,660.50.
- On Wednesday, January 14th, Grigorios Siokas acquired 493,495 shares of Cosmos Health stock. The stock was purchased at an average cost of $0.45 per share, with a total value of $222,072.75.
- On Monday, January 12th, Grigorios Siokas bought 113,185 shares of Cosmos Health stock. The shares were purchased at an average cost of $0.50 per share, for a total transaction of $56,592.50.
- On Thursday, January 8th, Grigorios Siokas bought 156,190 shares of Cosmos Health stock. The stock was purchased at an average price of $0.52 per share, for a total transaction of $81,218.80.
- On Wednesday, January 7th, Grigorios Siokas purchased 124,880 shares of Cosmos Health stock. The shares were purchased at an average price of $0.52 per share, with a total value of $64,937.60.
- On Tuesday, January 6th, Grigorios Siokas purchased 133,953 shares of Cosmos Health stock. The shares were purchased at an average cost of $0.54 per share, for a total transaction of $72,334.62.
- On Friday, December 19th, Grigorios Siokas acquired 88,314 shares of Cosmos Health stock. The stock was acquired at an average price of $0.49 per share, for a total transaction of $43,273.86.
- On Monday, December 15th, Grigorios Siokas bought 168,472 shares of Cosmos Health stock. The shares were acquired at an average cost of $0.42 per share, with a total value of $70,758.24.
- On Friday, November 28th, Grigorios Siokas bought 76,360 shares of Cosmos Health stock. The stock was acquired at an average price of $0.64 per share, for a total transaction of $48,870.40.
- On Tuesday, November 25th, Grigorios Siokas purchased 55,732 shares of Cosmos Health stock. The stock was acquired at an average cost of $0.63 per share, for a total transaction of $35,111.16.
Cosmos Health Stock Up 1.6%
Shares of NASDAQ:COSM opened at $0.51 on Tuesday. The company has a market capitalization of $18.95 million, a price-to-earnings ratio of -0.67 and a beta of 5.37. Cosmos Health Inc. has a 12-month low of $0.28 and a 12-month high of $1.32. The business has a 50-day moving average price of $0.53 and a 200 day moving average price of $0.74. The company has a current ratio of 0.99, a quick ratio of 0.84 and a debt-to-equity ratio of 0.25.
Cosmos Health (NASDAQ:COSM - Get Free Report) last posted its earnings results on Friday, November 14th. The company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.16). Cosmos Health had a negative net margin of 31.01% and a negative return on equity of 33.19%. The company had revenue of $17.11 million during the quarter, compared to analyst estimates of $16.40 million. Sell-side analysts expect that Cosmos Health Inc. will post -0.78 EPS for the current year.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings restated a "sell (d-)" rating on shares of Cosmos Health in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of "Sell".
Get Our Latest Stock Report on COSM
Institutional Investors Weigh In On Cosmos Health
A hedge fund recently raised its stake in Cosmos Health stock. Citadel Advisors LLC raised its holdings in Cosmos Health Inc. (NASDAQ:COSM - Free Report) by 133.1% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 225,507 shares of the company's stock after buying an additional 128,776 shares during the period. Citadel Advisors LLC owned approximately 0.65% of Cosmos Health worth $250,000 as of its most recent SEC filing. Institutional investors own 12.61% of the company's stock.
About Cosmos Health
(
Get Free Report)
Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
